Vascular ATP-sensitive K؉ channels are inhibited by multiple vasoconstricting hormones via the protein kinase C (PKC) pathway. However, the molecular substrates for PKC phosphorylation remain unknown. To identify the PKC sites, Kir6.1/SUR2B and Kir6.2/SUR2B were expressed in HEK293 cells. Following channel activation by pinacidil, the catalytic fragment of PKC inhibited the Kir6.1/SUR2B currents but not the Kir6.2/SUR2B currents. Phorbol 12-myristate 13-acetate (a PKC activator) had similar effects. Using Kir6.1-Kir6.2 chimeras, two critical protein domains for the PKC-dependent channel inhibition were identified. The proximal N terminus of Kir6.1 was necessary for channel inhibition. Because there was no PKC phosphorylation site in the N-terminal region, our results suggest its potential involvement in channel gating. The distal C terminus of Kir6.1 was crucial where there are several consensus PKC sites. Mutation of Ser-354, Ser-379, Ser-385, Ser-391, or Ser-397 to nonphosphorylatable alanine reduced PKC inhibition moderately but significantly. Combined mutations of these residues had greater effects. The channel inhibition was almost completely abolished when 5 of them were jointly mutated. In vitro phosphorylation assay showed that 4 of the serine residues were necessary for the PKC-dependent 32 P incorporation into the distal C-terminal peptides. Thus, a motif containing four phosphorylation repeats is identified in the Kir6.1 subunit underlying the PKC-dependent inhibition of the Kir6.1/ SUR2B channel. The presence of the phosphorylation motif in Kir6.1, but not in its close relative Kir6.2, suggests that the vascular K ATP channel may have undergone evolutionary optimization, allowing it to be regulated by a variety of vasoconstricting hormones and neurotransmitters.ATP-sensitive K ϩ (K ATP ) channels play an important role in vascular tone regulations (1-3). Such a function attributes to channel regulation by a variety of vasodilating and vasoconstricting hormones and neurotransmitters (3-7). Therefore, the understanding of the molecular basis for channel regulation has an impact on the design of therapeutic modalities by targeting at specific molecular substrates of the channel. It is known that the major isoform of K ATP channels in vascular smooth muscles is composed of Kir6.1 and SUR2B (8 -12). Genetic disruption of Kir6.1 or SUR2 indeed results in a phenotype of Prinzmetal angina with a high rate of sudden death (13,14), consistent with the importance of the channel in vascular regulations.Experimental evidence suggests that vasoconstrictors act on the vascular K ATP channel through the PKC 2 signaling system. Our previous studies have shown that the Kir6.1/SUR2B channel and its counterpart in vascular smooth muscle cells are inhibited by vasopressin and that channel inhibition can be abolished by specific PKC blockers (6). Similar observations have been made by other groups with endothelin (15), muscarinic M3 receptor agonist (16), and angiotensin II (17). The effect of angiotensin II on the vascul...